Panacea Biotec financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹200cr+19.7% on Q1 FY26
Net profit
₹2.2cr−44.4% on Q1 FY26
EBITDA margin
2.8%+3.6 pts on Q1 FY26
EPS
₹0.38−42.4% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue200167+19.7%
EBITDA5.7−1.2—
EBITDA margin2.8%−0.7%+3.6 pts
Profit before tax3.66.6−45.6%
Net profit2.24.0−44.4%
EPS₹0.38₹0.66−42.4%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹200 crNet profit₹2.2 crNet margin1.1%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,017————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
67.367.385.387.553.3
−6.0−6.0−4.2−3.8−3.5
23.723.722.221.020.2
1,967————
673640559559460
—+14.4%−0.0%+21.6%—
2.2−4.7−25.9−20.1−98.0
0.3%−0.7%−4.6%−3.6%−21.3%
−30.4−37.7−60.7−56.8−137
−8.9−7.2−8.7−1.5−33.8
−1.3%−1.1%−1.6%−0.3%−7.3%
−₹1.16−₹0.88−₹1.37−₹0.19−₹5.51
—+35.8%−615.4%+96.5%—
—16.7−27.4−0.1−423
—−54.1−50.3−77.7−41.0
−37.4−37.4−77.7−77.8−464
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health
₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,017 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————2,017.1
- Cash, Equiv & ST Investments53.387.585.367.367.3
+ Minority Interest-3.5-3.8-4.2-6.0-6.0
+ Total Debt20.221.022.223.723.7
Enterprise Value————1,967.4
Revenue460.0559.2559.1639.8672.6
Growth %, YoY—+21.6-0.0+14.4—
EBITDA-98.0-20.1-25.9-4.72.2
Margin %-21.30-3.59-4.63-0.730.33
EBIT-137.1-56.8-60.7-37.7-30.4
Net Income-33.8-1.5-8.7-7.2-8.9
Margin %-7.34-0.27-1.56-1.12-1.33
EPS, Adj (current shares)-5.51-0.19-1.37-0.88-1.16
Growth %, YoY—+96.5-615.4+35.8—
Cash from Operations-423.5-0.1-27.416.7—
Capital Expenditures-41.0-77.7-50.3-54.1—
Free Cash Flow-464.4-77.8-77.7-37.4-37.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Panacea Biotec financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Panacea Biotec (NSE: PANACEABIO) had a market capitalisation of ₹1,998 crore at the 29 October 2026 close (₹325.90 a share) and a price-to-book ratio of 2.39. In FY26 its consolidated net loss was ₹5.4 crore on revenue of ₹640 crore; in Q1 FY27 (April–June 2026) it was ₹2.3 crore, down 43.2% year on year. Its debt-to-equity ratio was 0.03 on 31 March 2026. Promoters held 72.48% of the shares on 30 September 2026.

Panacea Biotec Q1 FY27 results
filed 13 August 2026
Share price used
₹325.90 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Panacea Biotec at a glance · consolidated

Market cap
₹1,998 Crat ₹325.90 · 29 Oct close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
2.39book value ₹136.19 a share
ROE (FY26)
−0.6%+0.4 pts vs FY25ROCE −4.1%
Debt to equity
0.03net cash ₹50.7 Cr
Promoter holding
72.48%unchanged vs 30 Jun 202630 September 2026
Net worth
₹835 Cr0.0% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹37.4 Cr
EPS (FY26)
−₹0.88

Questions

What is the Panacea Biotec PE ratio today?

Panacea Biotec's PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹7.1 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹1,998 crore at ₹325.90 a share.

What is the Panacea Biotec PB ratio (price to book value)?

Panacea Biotec's price-to-book (PB) ratio is 2.39 at the 29 October 2026 close: a market capitalisation of ₹1,998 crore divided by shareholders' equity (book value) of ₹835 crore on 31 March 2026. That is a book value of ₹136.19 per share against a share price of ₹325.90.

What is the Panacea Biotec book value per share?

Panacea Biotec's book value per share was ₹136.19 on 31 March 2026: shareholders' equity of ₹835 crore divided by the 6.13 crore shares in issue, unchanged from ₹136.18 a year earlier. The share price at the 29 October 2026 close was ₹325.90.

What is the Panacea Biotec market cap?

Panacea Biotec's market capitalisation was ₹1,998 crore at the 29 October 2026 close: 6.13 crore shares at ₹325.90 each.

Is Panacea Biotec debt free?

No. Panacea Biotec had borrowings of ₹23.7 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.03. Its cash and current investments were ₹74.4 crore, so it held net cash of ₹50.7 crore.

What is the Panacea Biotec EPS?

Panacea Biotec's basic earnings per share (EPS) were −₹0.88 in FY26, against −₹1.37 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to −₹1.16.

What is the Panacea Biotec debt to equity ratio?

Panacea Biotec's debt-to-equity ratio was 0.03 on 31 March 2026: borrowings of ₹23.7 crore against total equity of ₹829 crore. A year earlier, on 31 March 2025, it was 0.03.

What is the Panacea Biotec net worth?

Panacea Biotec's net worth — shareholders' equity in its consolidated balance sheet — was ₹835 crore on 31 March 2026, unchanged from ₹835 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,998 crore at the 29 October 2026 close.

What is the Panacea Biotec free cash flow?

In FY26, Panacea Biotec generated ₹16.7 crore of cash from operations and spent ₹54.1 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹37.4 crore. In FY25 it was −₹77.7 crore.

What is the Panacea Biotec ROE and ROCE?

In FY26, Panacea Biotec's return on equity (ROE) was −0.6% and its return on capital employed (ROCE) was −4.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −1.0% and ROCE −6.6%.

What is the Panacea Biotec shareholding pattern?

On 30 September 2026, Panacea Biotec's shares were held by promoters 72.48%, foreign portfolio investors (FII/FPI) 2.75%, domestic institutions (DII) 2.47% (including mutual funds at 0.00%) and retail and other non-institutional investors 22.30%. Over the year, FII holding was up 1.69 percentage points from 1.06% and DII holding was up 0.66 percentage points from 1.81%.

What are the Panacea Biotec latest quarterly results?

Panacea Biotec's latest results are for Q1 FY27 (April–June 2026), filed on 13 August 2026: consolidated net profit ₹2.3 crore, down 43.2% from ₹4.1 crore in Q1 FY26; revenue from operations ₹200 crore, up 19.7% year on year.

What is the Panacea Biotec promoter holding?

Promoters held 72.48% of Panacea Biotec on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the Panacea Biotec revenue and profit in FY26?

In FY26 (April 2025–March 2026), Panacea Biotec's consolidated net loss was ₹5.4 crore, narrower than the loss of ₹8.4 crore in FY25, on revenue from operations of ₹640 crore (up 14.4%).

When are the Panacea Biotec next results?

Panacea Biotec has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does Panacea Biotec compare with its peers?

On FY26 consolidated figures, against Sai Parenterals, Hikal and Indoco Remedies: Panacea Biotec's operating margin of −5.9% is the lowest of the four (Sai Parenterals 5.7%, Hikal 3.3%, Indoco Remedies 0.8%; peer average 3.3%); its return on equity of −0.6% is the second highest of the four (Sai Parenterals 2.9%, Hikal −4.0%, Indoco Remedies −9.7%; peer average −3.6%).

Panacea Biotec vs Sai Parenterals: how do they compare?

In FY26, Panacea Biotec earned net profit of ₹5.4 crore on revenue of ₹640 crore, against ₹14.3 crore on ₹381 crore for Sai Parenterals. Panacea Biotec's operating margin was −5.9% (Sai Parenterals 5.7%) and its return on equity −0.6% (Sai Parenterals 2.9%). At the 29 October 2026 close, Panacea Biotec's market capitalisation was ₹1,998 crore against ₹2,234 crore for Sai Parenterals.

Where do these Panacea Biotec figures come from?

From Panacea Biotec's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.